AKERO AK-US-001-0105 (AKERO 105) trial is a Phase 3 clinical trial will investigate efruxifermin (EFX), a fibroblast growth factor 21 (FGF21) analog, for the treatment of patients with noncirrhotic MASH (F2-F3 fibrosis stages). The study is designed to assess whether once-weekly subcutaneous EFX can improve liver histology and metabolic markers in patients with moderate-to-advanced fibrosis. To participate in this trial, all individuals must meet the following criteria:
- Between age 18 - 80 years
- BMI ≥ 25
- Have a biopsy that proves noncirrhotic MASH in the F2-F3 fibrosis stages ≤ 180 days prior to screening
- No cirrhosis or other liver disease/HCC/diabetic mellitus type 1
To learn more please email: kianakhbari@arizona.edu